BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...
Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...
Hosted on MSN
Pfizer Stock Slips Premarket Despite Completing Metsera Deal; Investors React To BioNTech Stake Cut
・The Metsera buyout brings multiple obesity and cardiometabolic drug candidates into Pfizer’s pipeline, including a GLP-1 nearing Phase 3. ・Pfizer’s BioNTech position was reduced by 54.7%, leaving ...
LONDON (Reuters) -Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal. Last ...
Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage metabolic dysfunction-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback